Fresh filings reveal several institutional investors, including Man Group, are building new positions in DexCom as the FDA broadens access to its Stelo glucose sensor for children, intensifying competition in the growing continuous glucose monitoring sector.
DexCom is drawing renewed attention from institutional investors as fresh filings show several firms building new positions in the diabetes technology company, even as the U.S. Food and Drug Administration broadened access to its Stelo over-the-counter glucose sensor for children. The combination of buying interest and regulatory progress has sharpened focus on the company’s place in the fast-growing continuous glucose monitoring market.
Recent disclosures show Man Group added a large new stake in DexCom, while other investors also increased exposure during the summer. MarketBeat reported that SummitTX Capital and Centaurus Financial both expanded or initiated holdings earlier in 2026, suggesting that professional money managers still see room for the shares despite their recent strength. DexCom’s latest earnings also helped underpin that view, with the company beating Wall Street estimates on both profit and revenue.
The FDA’s June 12 decision marked a notable shift for Stelo, which became the first over-the-counter continuous glucose monitor cleared for children aged two and older who do not use insulin. The agency said the sensor is intended to improve glucose awareness, with each wearable device lasting up to 15 days. DexCom later said it planned a revamped Stelo app and wider international availability, signalling that the company sees the product as more than a niche adult wellness device.
That broader label matters because it extends DexCom beyond its core base of prescription CGM users. The company’s main systems remain aimed at people who need close blood sugar tracking, but Stelo gives it a route into a wider consumer and family market. For a business that depends on recurring sensor sales, any expansion in the addressable market can have an outsized effect on revenue over time.
Even so, analysts remain measured. The consensus rating cited in recent market data is “Moderate Buy”, with an average target price of $88.71. DexCom shares opened at $89.29 on August 28, placing them just above that level. That suggests investors are already pricing in a fair amount of optimism, with future gains likely to depend on adoption of Stelo, continued clinical use of CGM products and further execution on growth.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
